SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...
* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with...
SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage...
SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...
* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted ...
SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...
SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...
SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...
* 13 significant clinical milestones achieved year-to-date, including critical positive data read...
SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...
* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * ...
SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...